A growing body of research is reshaping how clinicians approach systemic lupus erythematosus (SLE), placing the dermatology industry at the center of this shift. A recent study led by researchers
At a recent Cleveland Clinic AI Summit, health care leaders painted a picture of artificial intelligence (AI) not as a replacement for clinicians, but as an enhancement, comparing it to
Artificial intelligence (AI) continues to make waves in medicine, offering powerful capabilities in image analysis, pattern recognition, and decision support. In dermatology and beyond, AI systems are increasingly promoted as
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition influenced by genetic, immunologic, and environmental factors. While dermatologists have long considered irritants and allergens in disease management, a growing
Emerging research is reframing how dermatologists should perceive psoriasis – not only as a dermatologic condition but also as one closely tied to metabolic health. Recent data from the UK
As summer approaches, dermatologists are positioned to lead the charge in educating patients about effective photoprotection strategies to prevent skin cancer. With over five million cases diagnosed annually in the
May marks Skin Cancer Awareness Month, a crucial period dedicated to educating the public about the risks of skin cancer and the importance of prevention and early detection. With over
As consumer demand for high-quality over-the-counter (OTC) skincare continues to surge, the 2025-2026 U.S. News & World Report rankings for Best OTC Medicine & Health Products provide valuable insight into
The integration of artificial intelligence into dermatology is revolutionizing the early detection and diagnosis of skin cancers. Recent advancements suggest that AI can serve as a valuable adjunct to traditional
The U.S. Food and Drug Administration (FDA) recently issued an alert regarding compounded topical finasteride products, warning health care providers, compounders, and consumers about potentially serious risks associated with their
The U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (prademagene zamikeracel), marking a historic milestone as the first and only autologous cell-based gene therapy for the treatment of wounds
Allergan Aesthetics, an AbbVie company, has announced the launch of an innovative Skin Quality Index—a universal vocabulary for skin quality designed to improve patient-provider communication and treatment outcomes. The initiative
The International League of Dermatological Societies (ILDS) recently published an updated position statement addressing the concerning rise in the misuse of topical corticosteroids as skin-bleaching products. Describing the issue as
A recent study has identified obesity as a significant contributor to the reduced long-term efficacy of biologic therapies in patients with severe plaque psoriasis, highlighting the need for more personalized
Molecular Instruments®, Inc. (MI), a leading innovator in bioimaging, has announced a major breakthrough in skin disease diagnostics. In collaboration with the Department of Dermatology at Yale School of Medicine,
Chronic hand eczema (CHE) is an often-overlooked skin condition that affects nearly 15.9 million people in the United States. Despite its prevalence, many healthcare providers struggle to fully comprehend the
During a recent investigation, the U.S. Food and Drug Administration (FDA) conducted testing on 95 acne products containing benzoyl peroxide to assess potential benzene contamination. The results, released on March
L’Oréal has voluntarily recalled all lots of its acne treatment, Effaclar Duo, in the U.S. due to concerns that the product may be contaminated with benzene, a known carcinogen. Effaclar
Research has shown that individuals with darker Fitzpatrick skin types (III-VI) face a higher risk of developing post-inflammatory hyperpigmentation (PIH). According to studies, this increased susceptibility is due to larger
Alphyn has announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for Zabalafin Hydrogel, a groundbreaking treatment for mild-to-moderate atopic dermatitis (AD).
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
